Navigation Links
ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Date:9/4/2012

BARCELONA, Spain, September 4, 2012 /PRNewswire/ --

  • E-52862 is a potent, highly selective NCE with a novel mechanism of action (MOA; Sigma 1 Receptor (S1R) antagonism) currently being evaluated for the treatment of pain
  • Key data are outlined from three Phase I studies involving 175 male and female human subjects
  • These studies demonstrate a favourable safety, tolerability, pharmacokinetic and pharmacodynamic profile for E-52862
  • Phase II clinical trials evaluating E-52862 are ongoing

ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology[1].

     (Logo: http://photos.prnewswire.com/prnh/20120904/554843)

Mariano Sust, M.D., corresponding author, stated that "E-52862 represents a NCE with a novel, unprecedented mechanism of action for pain of different aetiologies.  We are very encouraged by these results and look forward to future findings from the E-52862 clinical trial programme in due course."

To fully validate the safety and tolerability of E-52862, ESTEVE performed a rigorous phase I programme. This publication reports results from three, Phase I studies involving 175 human subjects. E-52862 demonstrated a favourable safety and tolerability profile across a robust panel of assessments including adverse event recording following questioning and spontaneous reporting; physical examinations; vital signs measurements; laboratory safety tests (haematology, blood coagulation, biochemistry, urinalysis); multiple psychometric tests; computerized cognitive evaluations (including assessment of executive function, working memory and learning, reaction time and psychomotor functions); and thorough cardiac monitoring
'/>"/>

SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ESTEVE Communicates its R&D Through a New Interactive Platform
2. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
5. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
6. Clinical Site Services, Industry Leader in Patient Enrollment Solutions, Announces New Website
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
9. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
10. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
(Date:8/26/2014)... 26, 2014 Vycom announced today that ... specializes in chemical process equipment, has selected its Flametec ... Facility for Rare Isotope Beams (FRIB). This involved ... line made with Vycom’s Flametec PVC-C and Kytec PVDF ... essential parts of FRIB’s linear accelerator (known as LINAC). ...
(Date:8/26/2014)... Trovagene, Inc. (NASDAQ:  TROV) presented data ... Assays to the Clinic with an oral ... Free Tumor DNA in Urine." In this presentation ... Cancer Monitoring (PCM) platform and results from several ... of tumor DNA mutations from urine samples of ...
(Date:8/26/2014)... REDWOOD CITY, Calif. , Aug. 26, 2014 ... the development and commercialization of oncology diagnostic products, ... Forum as a 2015 Technology Pioneer . ... Health is one of 24 companies across a ... this prestigious accolade. Guardant360 ® ...
Breaking Biology Technology:Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2
... Trius Therapeutics, Inc. today announced that it has been ... the Defense Threat Reduction Agency (DTRA), an agency within the ... directed against gram-negative bacterial pathogens. Trius may receive up to ... the new DTRA contract, which is funded as part of ...
... the United States, over the past four decades, have ... them involving bombs or explosives, says a new report ... Study of Terrorism and Responses to Terrorism (START). ... from the Center,s Global Terrorism Database (GTD), the world,s ...
... , May 18 Patient and professional ... marketplace on new medicines. Effectively collaborating with advocacy groups ... and is especially critical for socially sensitive conditions/therapies. " ... " is a 125-page report from Best Practices, LLC ...
Cached Biology Technology:Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics 2Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics 3US terror concentrated in New York City; bombs weapon of choice 2Educating the Marketplace Through Collaborations with Patient Advocacy Groups 2Educating the Marketplace Through Collaborations with Patient Advocacy Groups 3
(Date:8/26/2014)... People for the Ethical Treatment of Animals (PETA) and ... be in Prague this week at the 9th World ... Sciences presenting original research on alternatives to the use ... well as studies identifying problems with current laboratory oversight ... from August 24 to 28, 2014, PETA and PISC ...
(Date:8/25/2014)... study reveals that the US has experienced widespread ... prostate cancer in recent years. The BJU ... surgeries are more expensive than traditional surgeries, their ... surgeons began using robotic technologies in operations to ... use of such robotic-assisted radical prostatectomy (RARP) procedures ...
(Date:8/25/2014)... saying in the biofuels industry: "You can make ... new study may pave the way to challenging ... National Renewable Energy Laboratory (NREL) demonstrates a concept ... lignin into a variety of renewable fuels, chemicals, ... " Lignin Valorization Through Integrated Biological Funneling and ...
Breaking Biology News(10 mins):US has seen widespread adoption of robot-assisted cancer surgery to remove the prostate 2New process helps overcome obstacles to produce renewable fuels and chemicals 2
... requires 60 per cent less of the costly catalyst than ... researchers have not been able to achieve savings of this ... Tanja Kallio of Aalto University. Fuel cells could replace ... a fuel cell, chemical processes must be sped up by ...
... fast rate according to research done in Peru,s Cordillera ... currently shrinking by about one per cent a year, ... calculations. But despite this accelerated glacial shrinking, ... from the glacier into the Rio Santa in Northern ...
... Irvine, Calif., and Arlington, Texas -- Researchers at UC Irvine ... spinning microparticles can direct the growth of nerve fiber, a ... on a chip and improve methods for treating spinal or ... the Beckman Laser Institute and Medical Clinic at UCI, and ...
Cached Biology News:Researchers discover a way to significantly reduce the production costs of fuel cells 2Study reveals turn 'signals' for neuron growth 2
Request Info...
Cells are grown to a specified density and induced, when necessary. Protein expression samples are collected at 3 growth points and analyzed by SDS-PAGE/Coomassie....
... Service ECACC is able to accept cell lines ... cryo-storage. The cell lines must be accompanied by ... in accordance with the requirements of cGMP and ... mycoplasma, bacteria or fungi. What are the benefits ...
... has generated hybridomas against a large ... initiation, you are provided with personalized ... cell lines developed by Covance remain ... typical hybridoma development project has four ...
Biology Products: